INTRODUCTION
============

Inflammation is one of the common biological reactions that protect our body from infection of bacteria, virus, and fungi. When inflammation occurs, the body responds by activating many different types of immune cells to clear out pathogens. Macrophages, the most common inflammatory cells, play a critical role in removing infectious materials and activate other immune cells. For these processes, activated macrophages produce pro-inflammatory cytokines and inflammatory mediators such as nitric oxide (NO) ([@b37-bt-23-414]; Soler [@b25-bt-23-414]). New production of these molecules is regulated at the transcriptional level by controlling nuclear translocation and DNA binding activity of inflammation-regulatory transcription factors such as nuclear factor (NF-κB) and activator protein (AP-1). By the action of these proteins, mRNA levels of inflammatory genes, such as inducible NO synthase (iNOS), cyclooxygenase (COX)-2, and tumor necrosis factor (TNF)-α can be dramatically increased ([@b34-bt-23-414]; [@b35-bt-23-414]).

Flavonoids are plant pigments that possess various physiological effects including antioxidant, antiviral, anti-cancer, anti-bacterial and anti-inflammatory activities ([@b28-bt-23-414]; [@b8-bt-23-414]; [@b14-bt-23-414]; [@b11-bt-23-414]). Fisetin ([Fig. 1](#f1-bt-23-414){ref-type="fig"}) is one of the polyphenolic flavonoids, which are widely found in many fruits and vegetables such as strawberry, mango, and onion ([@b14-bt-23-414]; [@b25-bt-23-414]). It has also been reported that fisetin displays anti-oxidative, anti-inflammatory, and anti-proliferative activities ([@b14-bt-23-414]). In particular, several groups have suggested the anti-inflammatory role of fisetin occurs via suppression of NF-κB and AP-1 activation ([@b20-bt-23-414]), however, how fisetin blocks these pathways is not fully elucidated in terms of identifying direct target enzymes. In this study, therefore, we sought to identify the molecular targets of fisetin involved in the negative regulation of lipopolysaccharide (LPS)-stimulated macrophages.

MATERIALS AND METHODS
=====================

Materials
---------

Fisetin (purity: \>98%), polyethylenimine (PEI), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (a tetrazole) (MTT), and LPS (*E. coli* 0111:B4) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum (FBS) and RPMI1640 were obtained from GIBCO (Grand Island, NY, USA). Dulbecco's modified Eagle's medium (DMEM) was obtained from Thermo Fisher Scientific Inc. (Waltham, MA, USA). RAW264.7 (a mouse macrophage-like cell line) and HEK293 (a human embryonic kidney cell line) cells were purchased from ATCC (Rockville, MD, USA). All other chemicals used in this study were of analytical grade from Sigma Chemical Company. Phospho-specific or total-protein antibodies recognizing p65, p50, inhibitor of κBα (IκBα), Src, spleen tyrosine kinase (Syk), lamin A/C and β-actin were obtained from Cell Signaling Technology (Beverly, MA, USA).

Expression vectors and DNA transfection
---------------------------------------

Wild-type Src (Src-WT) was used as reported previously ([@b36-bt-23-414]). All constructs were confirmed by automated DNA sequencing. Overexpression experiments were performed with HEK293 cells (1×10^6^ cells/mL) by transfection with Src-WT using the PEI method in 12-well plates as reported previously ([@b30-bt-23-414]; [@b33-bt-23-414]). The cells were utilized for the experiments 24 h post-transfection. Fisetin was added to cells 24 h before termination.

Cell culture and drug preparation
---------------------------------

RAW264.7 cells were cultured in RPMI1640 with 10% heat-inactivated FBS and 1% penicillin/streptomycin at 37°C in 5% CO~2~. HEK293 cells were maintained in DMEM media supplemented with 5% heat-inactivated FBS and 1% penicillin/streptomycin at 37°C in 5% CO~2~. The stock solutions of fisetin for the *in vitro* experiments were prepared in dimethylsulfoxide (DMSO).

Determination of NO production
------------------------------

After pre-incubation of RAW264.7 cells (1×10^6^ cells/mL) for 18 h, fisetin was added to the cells for 30 min. After that, the cells were treated with LPS (1 μg/mL) for 24 h. The effect of fisetin (0 to 30 μM) on the production of NO was determined by analyzing NO levels using Griess reagents ([@b15-bt-23-414]; [@b42-bt-23-414]).

Cell viability test
-------------------

The cytotoxic effects of fisetin (0 to 30 μM) were then evaluated using a conventional MTT assay as previously reported ([@b27-bt-23-414]; [@b39-bt-23-414]; [@b23-bt-23-414]). For the final 3 h of culture, 10 μl of MTT solution (10 mg/mL in phosphate-buffered saline, pH 7.4) were added to each well. Reactions were stopped by the addition of 15% sodium dodecyl sulfate (SDS) into each well, solubilizing the formazan. The absorbance at 570 nm (OD~570--630~) was measured using a Spectramax 250 microplate reader (BioTex, Bad Friedrich-shall, Germany).

mRNA analysis using semi-quantitative and quantitative reverse transcriptase-polymerase chain reactions
-------------------------------------------------------------------------------------------------------

In order to determine cytokine mRNA expression levels, total RNA was isolated from LPS-treated RAW264.7 cells using TRIzol Reagent, according to the manufacturer's instructions. Total RNA was stored at −70°C until use. Semi-quantitative RT reactions were conducted as previously reported ([@b22-bt-23-414]). Quantification of mRNA was performed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) with SYBR Premix Ex Taq according to the manufacturer's instructions (Takara, Shiga, Japan) using a real-time thermal cycler (Bio-Rad, Hercules, CA, USA) as reported previously ([@b13-bt-23-414]). Semi-quantitative RT-PCR was conducted as previously reported with minor modifications ([@b31-bt-23-414]). All of the primers (Bioneer, Daejeon, Korea) used are listed in [Table 1](#t1-bt-23-414){ref-type="table"}.

Preparation of cell lysates and nuclear fractions for immunoblotting
--------------------------------------------------------------------

RAW264.7 or HEK293 cells (5×10^6^ cells/mL) were washed three times in cold phosphate buffered saline (PBS) and lysed in lysis buffer as reported previously ([@b19-bt-23-414]). Nuclear lysates were prepared using a three-step procedure ([@b1-bt-23-414]). After treatment, the cells were collected with a rubber policeman, washed with 1×PBS, and lysed in 500 μl of lysis buffer on ice for 4 min. During the second step, the pellet (the nuclear fraction) was washed once with wash buffer without Nonidet P-40. During the final step, the nuclei were resuspended in an extraction buffer consisting of the lysis buffer plus 500 mM KCl and 10% glycerol. The nuclei/extraction buffer mixture was frozen at −80°C then thawed on ice and centrifuged at 14,000 rpm for 5 min. The supernatant was collected as the nuclear extract. Whole-cell or nuclear lysates were then analyzed by a conventional immunoblotting method ([@b38-bt-23-414]). The total and phosphorylated levels of p65, p50, IκBα, Src, Syk, HA, lamin A/C, and β-actin were visualized using an ECL system (Amersham, Little Chalfont, Buckinghamshire, UK) as reported previously ([@b21-bt-23-414]).

*In vitro* kinase assay with purified enzymes
---------------------------------------------

In order to evaluate the inhibition of the kinase activities of Src or Syk using purified enzymes, the kinase profiler service from Millipore (Billerica, MA, USA) was used. Purified Src or Syk (human) (1--5 mU) were incubated with the reaction buffer in a final reaction volume of 25 μl. The reaction was initiated by the addition of Mg-ATP. After incubation for 40 min at room temperature, the reaction was stopped by the addition of 5 mL of a 3% phosphoric acid solution. Ten microliters of the reaction were then spotted onto a P30 Filtermat that was washed three times for 5 min in 75 mM phosphoric acid and once in methanol prior to drying and scintillation counting.

Statistical analyses
--------------------

All of the data presented in this paper are expressed as means ± SD. For statistical comparisons, results were analyzed using either ANOVA/Scheffe's *post-hoc* test or the Kruskal-Wallis/Mann-Whitney test. A *p*-value\<0.05 was considered to be statistically significant. All statistical tests were carried out using the computer program, SPSS (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

Effect of fisetin on inflammatory responses
-------------------------------------------

First, to confirm the function of fisetin as an inflammatory-response suppressor in macrophage cells, we tested its capability to suppress NO production in LPS-treated RAW264.7 cells. As expected, production of NO was dose-dependently decreased by fisetin in RAW264.7 cells stimulated by LPS ([Fig. 2A](#f2-bt-23-414){ref-type="fig"}). It was found that there was no cytotoxic activity of fisetin at its effective anti-inflammatory concentrations ([Fig. 2B](#f2-bt-23-414){ref-type="fig"}).

Effect of fisetin on transcriptional activation in LPS-treated RAW264.7 cells
-----------------------------------------------------------------------------

To check whether the anti-inflammatory effect of fisetin occurs at the transcriptional level, we determined the mRNA expression levels of inflammatory genes such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and tumor necrosis factor-α (TNF-α). As expected, the expression of inflammatory mediator genes was suppressed in cells treated with either 20 or 30 μM of fisetin according to both semi-quantitative ([Fig. 3A](#f3-bt-23-414){ref-type="fig"}) and real-time RT-PCR ([Fig. 3B](#f3-bt-23-414){ref-type="fig"}) analyses. We also examined transcription factor levels in nuclear extracts by immunoblotting analysis and found that fisetin treatment was capable of inhibiting the nuclear translocation of p65/NF-κB at 60 min but not of p50/NF-κB ([Fig. 3C](#f3-bt-23-414){ref-type="fig"}).

Effect of fisetin on the upstream signaling of NF-κB activation
---------------------------------------------------------------

Many studies have demonstrated that the NF-κB pathway is regulated by intracellular signaling cascades ([@b2-bt-23-414]; [@b40-bt-23-414]). These signaling cascades include Src, Syk, and IκBα. To identify fisetin-targeted molecules in this pathway, we confirmed the expression levels of these molecules by immunoblotting analysis. Expectedly, the phospho-IκBα level in fisetin-treated cells was clearly decreased at 5, 30, and 60 min ([Fig. 4A](#f4-bt-23-414){ref-type="fig"}). Also, the autophosphorylation levels of Src and Syk were strikingly suppressed by fisetin at 2 min, without decreasing total levels of Src and Syk ([Fig. 4B](#f4-bt-23-414){ref-type="fig"}).

Inhibition of Src and Syk kinase activity and overexpression of Src by fisetin
------------------------------------------------------------------------------

In order to confirm inhibitory activity of Src/Syk phosphorylation, we checked whether these enzymes can directly block the kinase activity of Src and Syk. As expected, the kinase activities of purified Src and Syk were completely inhibited by fisetin (30 μM). This result indicates that fisetin can act as a direct inhibitor of these enzymes ([Fig. 5A](#f5-bt-23-414){ref-type="fig"}). To further validate fisetin-mediated suppression of Src activity, we employed an overexpression strategy using HA-Src. We found that over-expressed Src increased the phospho-Src level and fisetin suppressed the phosphorylation of Src in a dose-dependent manner ([Fig. 5B](#f5-bt-23-414){ref-type="fig"}).

DISCUSSION
==========

It was reported that fisetin exhibits anti-inflammatory, anti-oxidative, and anti-proliferative activities ([@b25-bt-23-414]). In our study, this compound was revealed to significantly inhibit NO production in RAW264.7 cells without affecting their cell viability ([Fig. 2A, 2B](#f2-bt-23-414){ref-type="fig"}). In addition, mRNA expression levels of pro-inflammatory genes were decreased by fisetin ([Fig. 3A, 3B](#f3-bt-23-414){ref-type="fig"}). Additionally, the translocation of transcription factor p65, a subunit of NF-κB, into the nucleus was remarkably inhibited at 60 min ([Fig. 3C](#f3-bt-23-414){ref-type="fig"}), implying that NF-κB upstream signaling pathway may be targeted by fisetin treatment. Indeed, the phosphorylation of NF-κB regulatory upstream protein (IκBα), a key event for p65 translocation ([@b5-bt-23-414]), was decreased by fisetin ([Fig. 4A](#f4-bt-23-414){ref-type="fig"}). Similarly, it was also reported that fisentin exterts downregulation of interleukin-6 and TNF-α in LPS-activated RAW264.7 cells via suppression of NF-κB, although exact target protein was not fully identified ([@b20-bt-23-414]). Previous papers and our present results led us to hypothesize that early enzymes, activated within 5 min under LPS stimulation, could be regulated by fisetin.

Previously, we determined that Src and Syk are major NF-κB regulatory protein tyrosine kinases ([@b2-bt-23-414]; [@b40-bt-23-414]). In parallel, inhibitory compounds, such as carnosic acid and quercetin, and plant-derived extracts fro*m Evodia lepta, Artemisia asiatica*, and *Rhodomyrtus tomentosa*, which show anti-inflammatory activities, were found to suppress Src and Syk ([@b24-bt-23-414]; [@b7-bt-23-414]; [@b9-bt-23-414]; [@b41-bt-23-414]). These enzymes' active forms and pro-inflammatory cytokines were increased in response to LPS stimulation at early time points ([@b22-bt-23-414]). In particular, activated Src and Syk are known to be involved in regulation of IκBα-phosphorylation ([@b22-bt-23-414]). Therefore, we also tested whether fisetin is able to suppress the phosphorylation of Src and Syk, a hallmark to determine activated forms of Src and Syk ([@b2-bt-23-414]; [@b40-bt-23-414]). As expected, the phosphorylation of Src and Syk at 2 min was strongly suppressed by fisetin ([Fig. 4B](#f4-bt-23-414){ref-type="fig"}). Since the phosphorylation of these enzymes is generated by their catalytic enzyme activities ([@b2-bt-23-414]; [@b40-bt-23-414]), it is supposed that fisetin can directly diminish the enzyme activity of Src and Syk. To prove this possibility, we determined the kinase activity by a conventional enzyme assay with purified Src and Syk as reported previously ([@b16-bt-23-414]; [@b11-bt-23-414]). As [Fig. 5A](#f5-bt-23-414){ref-type="fig"} shows, the kinase activity of Src was strongly reduced by fisetin (30 μM), while Syk was suppressed up to 52%, indicating that Src is the more preferred target of fisetin. Validation of this was also performed by overexpression work with HA-Src-expressing construct and by exploration of NO inhibitory activity under the treatment of PP2, a Src inhibitor ([@b3-bt-23-414]). In fact, it was confirmed that transfection of Src cDNA increased the phosphorylation level of Src ([@b3-bt-23-414]; [@b6-bt-23-414]). Similarly, fisetin treatment dose-dependently inhibited the phosphorylation of Src raised by Src overexpression ([Fig. 5B](#f5-bt-23-414){ref-type="fig"}). PP2 also strongly blocked the release of NO in LPS-treated RAW264.7 cells ([Fig. 5C](#f5-bt-23-414){ref-type="fig"}) as reported previously ([@b37-bt-23-414]). Therefore, these results, and other previously reported results, strongly support that Src could be a major direct target of fisetin in its anti-inflammatory actions.

Our data, demonstrating fisetin's inhibitory potency and its anti-inflammatory mechanisms, strongly suggest that it can be developed as an anti-inflammatory drug. However, development of a single compound from natural plants as an anti-inflammatory drug is difficult due to high production cost and low purification yield. Although the amount of this compound is very low, it has been demonstrated that fisetin is one of the major anti-inflammatory components in various plants, such as *Muntingia calabura, Toxicodendron vernicifluum*, and *Rhus verniciflua*, with *in vitro* and *in vivo* anti-inflammatory activity ([@b26-bt-23-414]; [@b18-bt-23-414]). A recent trend in the pharmaceutical industry is discovering strategies to develop the natural plant itself as the new drug. Indeed, STILLEN^TM^ from Dong-A Pharmaceutical Co. in Korea, was developed from *Artemisiae argyi* Folium 14 years ago. The activity of this compound against gastric ulcer and gastritis is promising, even in the extract ([@b10-bt-23-414]). The active components of this extract are flavonoids eupatilin, jaceosidin, and luteolin ([@b29-bt-23-414]). Considering these, it is also proposed that fisetin-containing plants can be chosen as anti-inflammatory candidate herbal medicines. Numerous reports have proved that fisetin-containing *Rhus verniciflua* is orally effective against 2,4-dinitrofluorobenzene-induced allergic contact dermatitis and carrageenan-induced edema ([@b12-bt-23-414]; [@b26-bt-23-414]; [@b17-bt-23-414]). A chemical synthetic approach for mass production of fisetin and its derivatives was also reported previously ([@b4-bt-23-414]). Using this method, it is expected that fisetin can be prepared in a low-cost way. Although synthetic fisetin can be applied in industrial fields, extract formulas seem to be easier to develop and display more potent efficacy due to a mixture form with other active ingredients. Therefore, we will continue screening fisetin-rich plants by HPLC analysis and will prove their anti-inflammatory efficacy by using *in vitro* and *in vivo* experimental models.

In summary, we have demonstrated that fisetin can suppress IκBα phosphorylation, p65 translocation, inflammatory gene expression, and NO production by direct blockade of Src and Syk kinase activities as summarized in [Fig. 6](#f6-bt-23-414){ref-type="fig"}. Because fisetin shows potent anti-inflammatory activity, we suggest that fisetin-rich plants from edible sources could be applied to the development of therapeutic remedies to cure various inflammatory symptoms. Therefore, relevant works will be further proved in the future projects.
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![Chemical structure of fisetin.](bt-23-414f1){#f1-bt-23-414}

![The effect of fisetin on the production of NO and cell viability in LPS-stimulated RAW 264.7 cells. (A) RAW264.7 cells (1×10^6^ cells/mL) were treated with LPS (1 μg/mL) in the presence or absence of fisetin (0 to 30 μM) for 24 h. The supernatants were then collected, and the NO concentration in the supernatants was determined using the Griess assay. (B) RAW264.7 cells (1×10^6^ cells/mL) were treated with fisetin for 24 h, and cell viability was evaluated using the MTT assay. All data are expressed as the mean ± SD of experiments, which were performed with six samples. ^\*\*^*p*\<0.01 compared to normal or control groups.](bt-23-414f2){#f2-bt-23-414}

![The effect of fisetin on transcriptional activation in LPS-stimulated RAW264.7 cells. (A and B) The mRNA levels of iNOS, COX-2, and TNF-α expressed in LPS (1 μg/mL)-treated RAW264.7 cells in the presence or absence of fisetin (20 and 30 μM) were measured by RT-PCR (A) or real-time PCR (B). (C) The nuclear levels of p65 and p50 in RAW264.7 cells treated with LPS (1 μg/mL) in the presence or absence of fisetin (30 VM) were analyzed by immunoblotting analysis. Data (B) are expressed as the mean ± SD of experiments, which were performed with six samples. ^\*\*^*p*\<0.01 compared to normal or control groups.](bt-23-414f3){#f3-bt-23-414}

![The effect of fisetin on the upstream signaling cascade of NF-κB. (A and B) RAW264.7 cells were incubated with LPS (1 μg/mL) in the presence or absence of fisetin (30 μM) for 30 min. The total phospho-protein levels of Src, Syk, and IκBα from whole lysates were determined by immunoblotting analysis.](bt-23-414f4){#f4-bt-23-414}

![The effect of fisetin on the activity of Src and Syk. (A) Inhibitory activity of fisetin (30 μM) on the kinase activity of purified Src or Syk was examined by kinase assay. (B) Inhibitory activity of fisetin (20 and 30 μM) on the phosphorylation of overexpressed Src was determined by immunoblotting analysis. (C) RAW264.7 cells (1×10^6^ cells/mL) were treated with LPS (1 μg/mL) in the presence or absence of PP2 (10 and 20 μM) for 24 h. The supernatants were then collected, and the NO concentration in the supernatants was determined using the Griess assay. Data (A and C) are expressed as the mean ± SD of experiments, which were performed with six samples. ^\*^*p*\<0.05 and ^\*\*^*p*\<0.01 compared to normal or control groups.](bt-23-414f5){#f5-bt-23-414}

![Putative inhibitory pathway of fisetin in LPS-activated inflammatory events.](bt-23-414f6){#f6-bt-23-414}

###### 

PCR primers used in this study

  Name                               Sequence (5′ to 3′)
  ------- -------------------------- ------------------------
  iNOS    F                          GGAGCCTTTAGACCTCAACAGA
  R       TGAACGAGGAGGGTGGTG         
  TNF-α   F                          TGCCTATGTCTCAGCCTCTTC
  R       GAGGCCATTTGGGAACTTCT       
  COX-2   F                          GGGAGTCTGGAACATTGTGAA
  R       GCACATTGTAAGTAGGTGGACTGT   
  GAPDH   F                          CAATGAATACGGCTACAGCAAC
  R       AGGGAGATGCTCAGTGTTGG       

[^1]: The first two authors contributed equally to this work.
